Login / Signup

Twelve-Month Longitudinal Serology in SARS-CoV-2 Naïve and Experienced Vaccine Recipients and Unvaccinated COVID-19-Infected Individuals.

Zion Congrave-WilsonWesley A ChengYesun LeeStephanie PerezLauren TurnerCarolyn Jennifer Marentes RuizShirley MendietaAdam SkuraJaycee JumarangJennifer Del ValleJohn T KubaleEmma Kaitlynn AllenPaul Glyndwr ThomasAubree GordonPia S Pannaraj
Published in: Vaccines (2022)
Longitudinal data comparing SARS-CoV-2 serology in individuals following infection and vaccination over 12 months are limited. This study compared the magnitude, decay, and variability in serum IgG, IgA, and neutralizing activity induced by natural infection ( n = 218) or mRNA vaccination in SARS-CoV-2 naïve ( n = 143) or experienced ( n = 122) individuals over time using enzyme-linked immunosorbent assays and an in vitro virus neutralization assay. Serological responses were found to be highly variable after natural infection compared with vaccination but durable through 12 months. Antibody levels in vaccinated, SARS-CoV-2 naïve individuals peaked by 1 month then declined through 9 months, culminating in non-detectable SARS-CoV-2-specific serum IgA. Individuals with both infection and vaccination showed SARS-CoV-2-specific IgG and IgA levels that were more robust and slower to decline than the other groups; neutralizing activity remained highest in this group at 9 months past vaccination. These data reinforce the benefit of vaccination after SARS-CoV-2 recovery.
Keyphrases
  • sars cov
  • respiratory syndrome coronavirus
  • electronic health record
  • coronavirus disease
  • big data
  • machine learning
  • dengue virus
  • binding protein
  • artificial intelligence
  • zika virus